I
0.380
-0.01 (-3.77%)
| 前收盘价格 | 0.395 |
| 收盘价格 | 0.380 |
| 成交量 | 31,100,489 |
| 平均成交量 (3个月) | 109,483,325 |
| 市值 | 35,613,624 |
| 价格/销量 (P/S) | 122.70 |
| 股市价格/股市净资产 (P/B) | 8.48 |
| 52周波幅 | |
| 利润日期 | 15 May 2025 |
| 营业利益率 (TTM) | -20,952.04% |
| 稀释每股收益 (EPS TTM) | -1.23 |
| 总债务/股东权益 (D/E MRQ) | 22.79% |
| 流动比率 (MRQ) | 2.12 |
| 营业现金流 (OCF TTM) | -14.67 M |
| 杠杆自由现金流 (LFCF TTM) | -6.95 M |
| 资产报酬率 (ROA TTM) | -76.74% |
| 股东权益报酬率 (ROE TTM) | -201.87% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Incannex Healthcare Inc. | - | - |
AIStockmoo 评分
2.4
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 2.38 |
|
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Core |
| 内部持股比例 | 26.14% |
| 机构持股比例 | 8.65% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Revisor Wealth Management Llc | 30 Jun 2025 | 14,042 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合